ChromaDex Announces FDA Orphan Drug And Rare Pediatric Disease Designations For NRC In Treatment Of Ataxia Telangiectasia (AT)
Portfolio Pulse from Benzinga Newsdesk
ChromaDex has announced that the FDA has granted Orphan Drug and Rare Pediatric Disease designations for its product NRC in the treatment of Ataxia Telangiectasia (AT).
June 07, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ChromaDex has received FDA Orphan Drug and Rare Pediatric Disease designations for its product NRC in the treatment of Ataxia Telangiectasia (AT). This could potentially lead to market exclusivity and financial incentives.
The FDA designations can provide ChromaDex with market exclusivity, tax credits, and potential grants, which are significant financial incentives. This news is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100